Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967941 · ClinicalTrials.gov registry record
Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis
A clinical trial, sponsored by CAMC Health System.
- Completed
- Registry status
- 169
- Enrollment target
NCT00967941: Completed study, sponsored by CAMC Health System.
NCT00967941 is a clinical trial that has completed, run by CAMC Health System. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00967941 has completed, sponsored by CAMC Health System.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-08 |
What the finished NCT00967941 record still lists
NCT00967941 is an observational study that tracks outcomes without assigning an intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00967941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00967941 about?
NCT00967941 is a clinical study titled "Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis". This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.
What is the current status of trial NCT00967941?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2007-08. Estimated completion is 2010-08.
Who is sponsoring clinical trial NCT00967941?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia